54903-61-6

Usage

InChI:InChI=1/C10H9NO3/c1-6(12)7-3-4-8-9(5-7)14-10(13)11(8)2/h3-5H,1-2H3

Upstream product

• 95-55-6 2-amino-phenol 
• 54903-09-2 6-acetyl-3H-benzooxazol-2-one 
• 74-88-4 methyl iodide 
• 21892-80-8 3-methylbenzo[d]oxazol-2(3H)-one 
• 75-36-5 acetyl chloride 
• 64-19-7 acetic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 54903-57-0 3-hydroxy-4-methylaminoacetophenone 
• 80427-88-9 6-(p-chloro-cinnamoyl)-3-methylbenzoxazolinone 
• 80427-87-8 6-cinnamoyl-3-methylbenzoxazolinone 
• 80428-00-8 2,7-dioxo-3-methyl-5-phenyl-2,3,5,6-tetrahydrocyclopentabenzoxazole 
• 134541-21-2 3-methyl-7-oximino-2-oxo-5-phenyl-2,3,5,6-tetrahydrocyclopentabenzoxazole 
• 183488-18-8 5-(2-Chloro-phenyl)-3-methyl-5,6-dihydro-3H-indeno[5,6-d]oxazole-2,7-dione 
• 183488-19-9 5-(2-Chloro-phenyl)-3-methyl-5,6-dihydro-3H-indeno[5,6-d]oxazole-2,7-dione 7-oxime 
• 136629-00-0 7-(4-morpholino-2-methylenepropionyl)-2,4 dimethyl-2,3-dihydrobenzoxazin-<1,4>-3-one hydrochloride 
• 1393571-53-3 6-(4-((E)-3-(4-(4-fluorophenyl)piperazin-1-yl)-3-oxoprop-1-enyl)-1-phenyl-1H-pyrazole-3-yl)-3-methyl-2-oxo-3H-benzoxazolone 
• 1393571-54-4 6-(4-((E)-3-(4-(4-fluorobenzyl)piperazin-1-yl)-3-oxoprop-1-enyl)-1-phenyl-1H-pyrazole-3-yl)-3-methyl-2-oxo-3H-benzoxazolone 
• 1393571-55-5 6-(4-((E)-3-(4-(4-chlorobenzyl)piperazin-1-yl)-3-oxoprop-1-enyl)-1-phenyl-1H-pyrazole-3-yl)-3-methyl-2-oxo-3H-benzoxazolone 
• 1393571-56-6 6-(4-((E)-3-(4-(pyridin-4-yl)piperazin-1-yl)-3-oxoprop-1-enyl)-1-phenyl-1H-pyrazole-3-yl)-3-methyl-2-oxo-3H-benzoxazolone 
• 1393571-57-7 6-(4-((E)-3-(4-(4-tolyl)piperazin-1-yl)-3-oxoprop-1-enyl)-1-phenyl-1H-pyrazole-3-yl)-3-methyl-2-oxo-3H-benzoxazolone 
• 1393571-58-8 6-(4-((E)-3-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)-3-oxoprop-1-enyl)-1-phenyl-1H-pyrazole-3-yl)-3-methyl-2-oxo-3H-benzoxazolone 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of aminoarylthiazole derivatives as potential potentiators of the chloride transport defect in cystic fibrosis

Background: Cystic fibrosis (CF) is the autosomal recessive disorder most common in Caucasian populations. It is caused by mutations in the cystic fibrosis transmembrane regulator protein (CFTR). CFTR is predominantly expressed at the apical plasma membra

Synthesis of some novel benzoxazolinonylcarboxamides as potential anti-inflammatory agents

The synthesis of new 2(3H )-benzoxazolinonylcarboxamides starting from 2-amino-4,6-dimethylpyridine and 2(3H )-benzoxazolone which were designed as anti-inflammatory agents is described. These derivatives were synthesised from 2(3H )-(benzoxazolinon-6-yl)carboxylic acids, which were obtained by Friedel-Crafts acylation of 2(3H )-benzoxazolone derivatives with oxalyl chloride and acetylchloride in the presence of the AlCl3-DMF complex. The constitution of the products was supported by elemental analysis IR and 1H NMR spectral data.

Synthesis, anti-inflammatory, antiplatelet and in silico ealuations of (E)-3-(3-(2,3-dihydro-3-methyl-2-oxo-3H-benzoxazole-6-yl)-1-phenyl-1H-pyrazole- 4-yl)acrylamides

A series of (E) -3-(3-(2,3-dihydro-3-methyl-2-oxo-3H -benzoxazole-6-yl)-1- phenyl-1H -pyrazole-4-yl)acrylamides (7a-k) were synthesized and ealuated for their in itro inhibitory actiities on COX-1 and COX-2 isoforms using a human whole blood assay as well as their antiplatelet profile against human platelet aggregation using arachidonic acid as agonists. Among the synthesized deriaties 7a-k, especially compound 7g exhibited dual anti-inflammatory and antiplatelet actiity with selectie COX-2 inhibition. TUeBITAK.

Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors

Three novel series of diaryl heterocyclic derivatives bearing the 2-oxo-5H-furan, 2-oxo-3H-1,3-oxazole, and 1H-pyrazole moieties as the central heterocyclic ring were synthesized and their in vitro inhibitory activities on COX-1 and COX-2 isoforms were evaluated using a purified enzyme assay. The 2-oxo-5H-furan derivative 6b was identified as potent COX inhibitor with selectivity toward COX-1 (COX-1 IC50 = 0.061 μM and COX-2 IC 50 = 0.325 μM; selectivity index (SI) = 0.19). Among the 1H-pyrazole derivatives, 11b was found to be a potent COX-2 inhibitor, about 38 times more potent than Rofecoxib (COX-2 IC50 = 0.011 μM and 0.398 μM, respectively), but showed no selectivity for COX-2 isoform. Compound 11c demonstrated strong and selective COX-2 inhibitory activity (COX-1 IC 50 = 1 μM, COX-2 IC50 = 0.011 μM; SI = ～92). Molecular docking studies of compounds 6b and 11b-d into the binding sites of COX-1 and COX-2 allowed to shed light on the binding mode of these novel COX inhibitors.

Synthesis of 1,11-dihydro-2H-[1,3]oxazolo[4′,5′:5,6]indeno[1,2- b]quinolin-2-ones with potential topoisomerase I inhibitory activity

A series of 1,11-dihydro-2,11-[1,3]oxazolo[4′,5′:5,6]indeno[1, 2-b]quinolin-2-ones were prepared by means of Friedlaender condensations. The starting materials for the preparations were commercial substituted-2- aminoacetophenones and various 5,6-dihydro-2H-indeno[5,6-d][l,3]oxazole-2,7(3H)- diones that were synthesized from 2(3H)-benzoxazolones or their N-methyl analogues. Thieme Verlag Stuttgart.

NOVEL CARBAPENEM COMPOUND

A carbapenem compound represented by a following formula [1], wherein R1 is C1 to C3 alkyl or C1 to C3 alkyl substituted by hydroxy. R is hydrogen atom or a group which regenerates a carboxyl group by

Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

Friedel-crafts acylation of 2(3H)-benzoxazolone: Investigation of the role of the catalyst and microwave activation

To study the scope and limitations of the use of complexed species of AlCl3 in Friedel-Crafts reactions, we investigated the acctylation and benzoylation of 2(3H)-benzoxazolone and 3-methyl-2(3H)-benzoxazolone varying the amide complexing agent. We replaced dimethylformamide by N-methylformamide, dimethylacetamide, pyrrolidone, N-methylpyrrolidone, tetramethylurea, and dimethylsulfoxide. However, there was no particular advantage of substituting dimethylformamide by another amide ligand. This can probably be ascribed to the fact that the complex formed between AlCl3 and the complexing agent becomes too stable. Alternatively, a route using polyphosphoric acid and microwave activation was explored. The major advantage of running the reaction in a microwave oven was that a good yield was reached in a rather short period of time.

A Convenient and Efficient Method for the Preparation of 6-Acyl-2(3H)-benzoxazolones

Benzoxazolinone derivatives have been found to exhibit various pharmacological properties and 6-acyl-2(3H)-benzoxazolones are considered as key starting materials for the preparation of these compounds.Reported here are the optimal conditions for a regioselective acylation at the 6-position of the benzoxazolinone ring.A general method leading to the expected products in excellent yields consists in using a mixture of aluminum chloride-dimethylformamide as catalyst and acid anhydrides or chlorides as acylating agents.